217 related articles for article (PubMed ID: 17435179)
1. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.
Sampson JH; Raghavan R; Brady ML; Provenzale JM; Herndon JE; Croteau D; Friedman AH; Reardon DA; Coleman RE; Wong T; Bigner DD; Pastan I; Rodríguez-Ponce MI; Tanner P; Puri R; Pedain C
Neuro Oncol; 2007 Jul; 9(3):343-53. PubMed ID: 17435179
[TBL] [Abstract][Full Text] [Related]
2. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning.
Sampson JH; Brady ML; Petry NA; Croteau D; Friedman AH; Friedman HS; Wong T; Bigner DD; Pastan I; Puri RK; Pedain C
Neurosurgery; 2007 Feb; 60(2 Suppl 1):ONS89-98; discussion ONS98-9. PubMed ID: 17297371
[TBL] [Abstract][Full Text] [Related]
3. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
Kunwar S; Chang SM; Prados MD; Berger MS; Sampson JH; Croteau D; Sherman JW; Grahn AY; Shu VS; Dul JL; Husain SR; Joshi BH; Pedain C; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E15. PubMed ID: 16709020
[TBL] [Abstract][Full Text] [Related]
4. Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin.
Sampson JH; Raghavan R; Provenzale JM; Croteau D; Reardon DA; Coleman RE; Rodríguez Ponce I; Pastan I; Puri RK; Pedain C
AJR Am J Roentgenol; 2007 Mar; 188(3):703-9. PubMed ID: 17312057
[TBL] [Abstract][Full Text] [Related]
5. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
Kunwar S; Prados MD; Chang SM; Berger MS; Lang FF; Piepmeier JM; Sampson JH; Ram Z; Gutin PH; Gibbons RD; Aldape KD; Croteau DJ; Sherman JW; Puri RK;
J Clin Oncol; 2007 Mar; 25(7):837-44. PubMed ID: 17327604
[TBL] [Abstract][Full Text] [Related]
6. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.
Parney IF; Kunwar S; McDermott M; Berger M; Prados M; Cha S; Croteau D; Puri RK; Chang SM
J Neurosurg; 2005 Feb; 102(2):267-75. PubMed ID: 15739554
[TBL] [Abstract][Full Text] [Related]
7. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Vogelbaum MA; Sampson JH; Kunwar S; Chang SM; Shaffrey M; Asher AL; Lang FF; Croteau D; Parker K; Grahn AY; Sherman JW; Husain SR; Puri RK
Neurosurgery; 2007 Nov; 61(5):1031-7; discussion 1037-8. PubMed ID: 18091279
[TBL] [Abstract][Full Text] [Related]
8. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
Sampson JH; Akabani G; Archer GE; Berger MS; Coleman RE; Friedman AH; Friedman HS; Greer K; Herndon JE; Kunwar S; McLendon RE; Paolino A; Petry NA; Provenzale JM; Reardon DA; Wong TZ; Zalutsky MR; Pastan I; Bigner DD
Neuro Oncol; 2008 Jun; 10(3):320-9. PubMed ID: 18403491
[TBL] [Abstract][Full Text] [Related]
9. Poor drug distribution as a possible explanation for the results of the PRECISE trial.
Sampson JH; Archer G; Pedain C; Wembacher-Schröder E; Westphal M; Kunwar S; Vogelbaum MA; Coan A; Herndon JE; Raghavan R; Brady ML; Reardon DA; Friedman AH; Friedman HS; Rodríguez-Ponce MI; Chang SM; Mittermeyer S; Croteau D; Puri RK;
J Neurosurg; 2010 Aug; 113(2):301-9. PubMed ID: 20020841
[TBL] [Abstract][Full Text] [Related]
10. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.
Kioi M; Husain SR; Croteau D; Kunwar S; Puri RK
Technol Cancer Res Treat; 2006 Jun; 5(3):239-50. PubMed ID: 16700620
[TBL] [Abstract][Full Text] [Related]
11. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
Shimamura T; Husain SR; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016
[TBL] [Abstract][Full Text] [Related]
12. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
Kunwar S; Chang S; Westphal M; Vogelbaum M; Sampson J; Barnett G; Shaffrey M; Ram Z; Piepmeier J; Prados M; Croteau D; Pedain C; Leland P; Husain SR; Joshi BH; Puri RK;
Neuro Oncol; 2010 Aug; 12(8):871-81. PubMed ID: 20511192
[TBL] [Abstract][Full Text] [Related]
13. Cintredekin besudotox in treatment of malignant glioma.
Mut M; Sherman JH; Shaffrey ME; Schiff D
Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792
[TBL] [Abstract][Full Text] [Related]
14. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors.
Ferguson S; Lesniak MS
Curr Drug Deliv; 2007 Apr; 4(2):169-80. PubMed ID: 17456036
[TBL] [Abstract][Full Text] [Related]
15. Influence of an intratumoral cyst on drug distribution by convection-enhanced delivery: case report.
Ivasyk I; Morgenstern PF; Wembacher-Schroeder E; Souweidane MM
J Neurosurg Pediatr; 2017 Sep; 20(3):256-260. PubMed ID: 28686124
[TBL] [Abstract][Full Text] [Related]
16. Convection-Enhanced Delivery for Management of Malignant Gliomas.
Prabhu SS
Prog Neurol Surg; 2018; 32():152-158. PubMed ID: 29990981
[TBL] [Abstract][Full Text] [Related]
17. Convection-enhanced Delivery of Therapeutics for Malignant Gliomas.
Saito R; Tominaga T
Neurol Med Chir (Tokyo); 2017 Jan; 57(1):8-16. PubMed ID: 27980285
[TBL] [Abstract][Full Text] [Related]
18. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies.
Kunwar S
Acta Neurochir Suppl; 2003; 88():105-11. PubMed ID: 14531568
[TBL] [Abstract][Full Text] [Related]
19. Future of convection-enhanced delivery in the treatment of brain tumors.
Bidros DS; Liu JK; Vogelbaum MA
Future Oncol; 2010 Jan; 6(1):117-25. PubMed ID: 20021213
[TBL] [Abstract][Full Text] [Related]
20. Convection-enhanced delivery in the treatment of malignant glioma.
Lopez KA; Waziri AE; Canoll PD; Bruce JN
Neurol Res; 2006 Jul; 28(5):542-8. PubMed ID: 16808887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
